In a meta-analysis reported in The Lancet Oncology, Mastrantoni et al identified first-line chemotherapy regimens associated with better outcomes in patients with unresectable advanced or metastatic pancreatic cancer.
A recent analysis of pancreatic cancer data in young adults (aged 15–39) has found that although there is an increase in incidence, the mortality rate remains stable. According to Patel et al, who published their findings in the Annals of Internal Medicine, the rise in incidence is primarily due to an increase in the detection of smaller, early-stage endocrine cancer, and not an increase in pancreatic adenocarcinoma. The investigators explained that their findings reflect the detection of previously undetected disease, rather than a true increase in cancer occurrence.
The University of Cincinnati Cancer Center announced the launch of a new study funded by a $2.3 million National Cancer Institute (NCI) grant to develop a novel technique to visualize where genetically modified immune cells go after being administered in patients with cancer.
Researchers have developed an artificial intelligence (AI)-powered computational program that may be capable of predicting the activity of thousands of genes within tumor cells based on standard microscopy images of a biopsy, according to a recent study published by Pizurica et al in Nature Communications. The findings demonstrated that the novel tool may use routinely collected biopsy images to predict genetic variations in breast cancers as well as patient outcomes.
In a study reported in JAMA Network Open, Zhu et al found that cancer-specific mortality rates have decreased overall among U.S. Asian and Pacific Islander populations during recent years, although increases in cancer-specific mortality have been reported for some cancers.
The American Society of Hematology (ASH) will recognize exemplary hematologists who have made significant contributions to the field with several honorific awards at the 2024 ASH Annual Meeting and Exposition, being held December 7–10 in San Diego. Mohandas Narla, DSc “ASH is honored to...
Kazuki Nozawa, MD Question: Based on NATALEE and monarchE data, is there still a need for neoadjuvant chemotherapy in hormone receptor (HR)-positive, HER2-negative early breast cancer? Answer: In monarchE trial, the CDK4/6 inhibitor abemaciclib combined with endocrine therapy demonstrated...
Ann H. Partridge, MD, MPH, FASCO Lisa Campo-Engelstein, PhD Kara N. Goldman, MD “Cancer in young adults is more complicated in part [because of the risk of] infertility and premature menopause,” commented Ann H. Partridge, MD, MPH, FASCO, Interim Chair, Department of Medical...
While clinical trials emphasize improvement in cure rates for patients with advanced classical Hodgkin lymphoma, an important goal is reducing the potential long-term effects of treatment. — Iris Isufi, MD Tweet this quote “While clinical trials emphasize improvement...
Investigators have found that among all cancer survivors, male adolescents and young adults (AYAs) may have the highest rate of suicide-related mortality, according to a recent study published by Matsuo et al in JAMA Network Open. Cancer is becoming more common among young patients, and cancer...
In addition to our in-depth analysis of important clinical trials presented at the European Society for Medical Oncology (ESMO) Congress 2024, there is always room for more coverage from The ASCO Post, including these brief summaries of other presentations of interest. They focus on a potential...
The National Comprehensive Cancer Network (NCCN) took part in the 2024 International Congress of the Asian Oncology Society and the 2024 Chinese Congress on Holistic Integrative Oncology, which highlighted international collaborations to improve cancer therapy and outcomes across China and Asia....